-
Article | 2017.09.12
Pasteur-Paris University enrollment 2018
The 2017-2018 call for enrollment of students in October 2018 is open.
-
Document de presse | 2018.05.31
Professor Christine Petit receives the 2018 Kavli Prize
The Institut Pasteur, the Collège de France, the French Academy of Sciences and Inserm are honored to announce that the Norwegian Academy of Science and Letters has decided to award the 2018 Kavli Prize in Neuroscience to Christine Petit for her pioneering work on the molecular and neural mechanisms of hearing. This prize, which is awarded every two years, consists of a $1 million (U.S.) fund...
-
Portrait | 2019.02.12
An Epidemiologist Faces Ebola in The Democratic Republic of the Congo
Ebola has battered the Democratic Republic of the Congo for many months, from the outbreak that ended in July 2018 to the epidemic currently raging. These are reminders that there is progress to be made in terms of controlling and understanding this deadly infectious disease. In 2018, during the epidemic in the north west of the country, Dr. Amber Kunkel, a scientist from the Institut Pasteur in...
-
Portrait | 2022.12.13
Pierre-Marie Lledo: a neuro-optimist in work and in life
Perception, emotions, behavior, decision-making, memory, good mental health, depression – these are some of the research topics that interest Pierre-Marie Lledo. With his team of biologists, physicians, mathematicians, biophysicists and biochemists, he is working to uncover some of the most intimate mechanisms in the brain.
-
Document de presse | 2023.09.28
Malaria: treatment of Plasmodium falciparum malaria patients under threat in the Horn of Africa
Diagnosis of Plasmodium falciparum malaria using rapid diagnostic tests and treatment with artemisinin derivatives, the main component of the malaria treatments recommended by the World Health Organization (WHO), are under threat in the Horn of Africa. Scientists from the Laboratory of Parasitology and Medical Mycology at the University of Strasbourg and Strasbourg University Hospital, in...
-
News | 2023.12.18
Climate and health: the latest on a silent epidemic
While the main outcome of COP28 was an agreement calling on the parties to "transition away from fossil fuels" with the aim of limiting climate change, it was also the first COP to include a Health Day. Rising global temperatures, extreme meteorological phenomena and ecosystem change are not merely environmental concerns. They are catalysts of a silent epidemic that is affecting human health....
-
Document de presse | 2025.05.29
The plague bacillus became less virulent, prolonging the duration of two major pandemics
Scientists at the Institut Pasteur and McMaster University have discovered that the evolution of a gene in the bacterium that causes bubonic plague, Yersinia pestis, may have prolonged the duration of two major pandemics. They have demonstrated that modifying the copy number of a specific virulence gene increases the length of infection in affected individuals. It is thought that this genetic...
-
Article | 2023.02.23
One Health-Emerging Infectious Diseases Graduate School (1H-EID)
The new Graduate School "One Health in Emerging Infectious Diseases" (1H-EID) is entirely dedicated to EIDs with a multidisciplinary approach. This Graduate School offers a high-level educational program based on research, to train future researchers, health professionals and decision-makers.The aim of 1H-EID will be to form a community of frontline actors, researchers and decision-makers,all...
-
Article | 2016.11.17
Board of Governors: Missions and composition
The Board of Governors is responsible for the affairs of Institut Pasteur. It approves the strategic orientations presented by the President. It approves budgets and financial statements.
-
News | 2026.03.12
COVID-19: a new strategy under investigation to tackle all variants
Scientists at the Institut Pasteur have developed an innovative strategy to combat SARS-CoV-2. Rather than targeting a virus in constant mutation, they propose blocking the gateway used by the virus to penetrate our cells. This is achieved by nasal administration of an antibody that protects against all known variants, paving the way for new therapies aimed at vulnerable individuals. This work,...